This is a nootropic drug that promotes memory consolidation, can facilitate the learning process, increase the resistance of brain tissue to toxic effects, and has anticonvulsant activity.
The drug is produced on the basis of the Irkutsk enterprise of the Pharmasyntez Group of Companies. The granulation section of the workshop for sterile and solid dosage forms is equipped with the latest Swiss equipment, all products are manufactured in strict accordance with GMP standards, the company emphasized.
In December, it is planned to release the second batch of the drug with a volume of 40 thousand packages.
The drug has become the second nootropic in the Pharmasyntez line: since 2022, the company has been producing a nootropic drug with the active substance citicoline, which can be used for ischemic stroke, traumatic brain injury, and cognitive impairment.